Evidence map›Paper›PMID 42750705›Full record

ArticleFrontiers in microbiology2026

Establishment of epidemiological cut-off values of cefotaxime-sulbactam against

Menglan Zhou, Yun Wu, Wei Kang, Qiwen Yang, Bo Zheng, Fupin Hu, Yunsong Yu, Chao Zhuo, Ge Zhang, Jingjia Zhang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Menglan Zhou *Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yun Wu *Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wei Kang *Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Qiwen YangDepartment of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Bo ZhengInstitute of Clinical Pharmacology, Peking University, Beijing, China.
Fupin HuHuashan Hospital of Fudan University, Shanghai, China.
Yunsong YuZhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
Chao ZhuoDepartment of Infectious Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Ge ZhangDepartment of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jingjia ZhangDepartment of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jin LiDepartment of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Tong WangDepartment of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Haotian GaoDepartment of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yingchun XuDepartment of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To establish the epidemiological cut-off (ECOFF) value of cefotaxime-sulbactam against Methods: A total of 1,770 non-duplicate clinical isolates were collected from five laboratories in four cities in China. Minimum inhibitory concentrations (MICs) of cefotaxime-sulbactam were determined independently using the broth microdilution method according to EUCAST standards. For Results: Statistical endpoints at 95%, 97.5%, 99%, 99.5%, and 99.9% were calculated. The final ECOFFs were assigned based on concordance between ECOFFinder-derived estimates and visual inspection, using the 99% endpoint as the primary statistical estimate. The ECOFFs were 0.25/4 mg/L for Conclusion: ECOFFs of cefotaxime-sulbactam were established for seven clinically important bacterial species. These results provide essential reference values for distinguishing wild-type from non-wild-type isolates and support future breakpoint-setting and antimicrobial resistance surveillance.

Indexed as

acinetobacter baumanniicefotaximecefotaxime-sulbactamECOFFepidemiological cut-off

Identifiers

PMID42750705
PMCPMC13578078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.